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Small round blue cell tumours: diagnostic and prognostic usefulness of the expression
of B7-H3 surface molecule
Aims: To assess whether the expression of B7-H3
surface molecule could improve differential diagnosis
of small cell round tumours.
Methods and results: One hundred and one well-char-
acterized parafﬁn-embedded small round cell tumours,
stored in the pathology archive of the Gaslini Institute,
were immunohistochemically analysed with the 5B14
monoclonal antibody, which recognizes the surface
molecule B7-H3. All lymphoblastic lymphomas and
the blastematous component of Wilms’ tumours were
completely negative and a few Ewing’s sarcoma and
Burkitt’s lymphoma specimens showed focal positivity,
whereas 74% of neuroblastomas, 67% of rhabdo-
myosarcomas and 100% of medulloblastomas were
positive. The pattern of immunoreactivity of 5B14 mAb
observed in rhabdomyosarcoma, neuroblastoma and
medulloblastoma specimens was limited to the cyto-
plasmic membrane, and in neuroblastomas areas of
rosette formation or of ganglion differentiation were
preferentially stained. Interestingly, in neuroblastoma
patients high expression of the antigen recognized by
the 5B14 mAb was associated with a worse event-free
survival.
Conclusions: The 5B14 mAb represents an additional
tool for the differential diagnosis of small round cell
tumours and might be useful in identifying neuroblast-
oma patients at risk of relapse who may take advantage
of more careful follow-up.
Keywords: B7-H3, diagnosis, neuroblastoma, small round cell tumours
Abbreviations: MKI, mitotic karryhoretic index; NB, neuroblastoma; NK, natural killer; NSE, neuron-speciﬁc
enolase; PNET, primitive neuroectodermal tumour
Introduction
Small round blue cell tumours of childhood include
neuroblastoma (NB), rhabdomyosarcoma, non-Hodg-
kin’s lymphoma, Ewing’s sarcoma and the closely
related primitive neuroectodermal tumour (PNET) and
the blastemic component of Wilms’ tumour.
1 The
tumours have similar appearance by light microscopy
and are often indistinguishable by common immuno-
cytochemical markers. Moreover, diagnosis, which is
often based on the clinical features of the tumours,
2
may be difﬁcult for those presenting in an unusual
clinical context.
For differential diagnosis a panel of antibodies
that recognize various tumour-associated markers is
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(NSE) and GD2, which are present in NB and
sometimes in osteosarcomas and rhabdomyosarc-
omas;
2,3 CD99 expressed by Ewing’s sarcoma and
by some PNETs;
4,5 NB84 expressed by NB cells
and sporadically by Ewing’s and PNETs;
6 and desmin
and cytokeratin present in desmoplastic tumours.
7
However, none of these markers has, by itself,
clinical utility in unambiguously differentiating small
round blue cell tumours.
8
We recently isolated a novel monoclonal antibody
termed 5B14,
9 which speciﬁcally recognizes a surface
glycoprotein termed B7-H3. This molecule is an
additional member of the B7 family, which also
includes B7-1 (CD80) and B7-2 (CD86).
10 Unlike
most B7 members, whose receptors have been
identiﬁed, B7-H3 represents an orphan ligand. On
the other hand, functional data suggest that T and
natural killer (NK) lymphocytes express speciﬁc
receptor(s) displaying either an inhibitory or co-
stimulatory function.
11,12 In particular, B7-H3 ex-
pressed at the tumour cell surface exerts a protective
role in NK-mediated lysis.
9 Notably, the mAb selec-
tively stains NB cells inﬁltrating the bone marrow of
stage 4 patients.
13
Differentiating a blue cell tumour from others is a
diagnostic challenge when considering that both
treatment and prognosis vary greatly among these
tumours. In this study we evaluated the potential use of
5B14 mAb for diagnostic and ⁄ or prognostic purposes.
We analysed the expression of B7-H3 in a large
number of parafﬁn-embedded small round blue cell
tumours. Tumour specimens included lymphoblastic
and Burkitt’s lymphomas, blastemic component of
Wilms’ tumour, primary NB, rhabdomyosarcomas
and medulloblastomas.
Material and methods
One hundred and one previously diagnosed small
round blue cell parafﬁn-embedded tumours, stored in
the Department of Pathology of the Gaslini Institute,
were analysed. These included seven lymphoblastic
lymphomas, 11 Burkitt’s lymphomas, eight Wilms’
tumours, six PNET ⁄ Ewing’s sarcomas, nine rhabdo-
myosarcomas, seven medulloblastomas and 53 NB. All
NB tumours were schwannian stroma poor with
different differentiation grades and different mitotic
karryoretic indices (MKI); 15 were stage 1, 11 stage 2,
one stage 3, 20 stage 4 and six stage 4s, as assessed
according to International Neuroblastoma Staging
System criteria.
14 Only four of the 53 NB specimens
were Myc-N ampliﬁed.
immunohistochemistry
5B14 mAb (anti-B7H3, IgM) was obtained by immu-
nizing a 5-week-old BALB ⁄ c mouse with the ACN
human neuroblastoma cell line, as previously
described.
9
Formalin-ﬁxed parafﬁn-embedded tissue sections
were de-parafﬁnized, rehydrated through graded etha-
nol solutions and treated in 3% H2O2 to block
endogenous peroxidase. Immunohistochemical label-
ling was performed by a three-step indirect immuno-
peroxidase technique. Once hydrated, sections were
heated for 30 min at 99 C in citrate buffer solution, pH
6.0 (Dako, Glostrup, Denmark) and incubated over-
night at 4 C with a 1:2000 dilution of puriﬁed 5B14
mAb (0.5 mg ⁄ ml). After washing, sections were incu-
bated for 30 min at room temperature with anti-mouse
antibody conjugated to peroxidase-labelled dextran
polymer (Dako). After washing, the slides were incu-
bated with the diaminobenzidine substrate at room
temperature. Slides were counterstained with Mayer’s
haematoxylin. Negative controls, consisting of slides
incubated with mouse normal serum (X0910; Dako),
were always run simultaneously.
grading analysis
The immunohistochemical results were classiﬁed
using two different systems. With one system reac-
tivity was qualitatively scored as 0 in the absence of
reactivity; one in the presence of weak and partial
membranous reactivity in >10% of cells; two when
moderate membranous reactivity was detected in
>10% of cells; and three when intense membranous
reactivity occurred in >10% of cells. With the second
system, reactivity was graded semiquantitatively as:
± with 10–25% positive tumour cells; + with 25–
50% positive tumour cells; ++ with 50–75% positive
tumour cells; and +++ with 75–100% positive
tumour cells.
survival and statistical analysis
Clinical data of NB patients were retrieved from the
Italian neuroblastoma registry, which collects informa-
tion on clinical and biological characteristics of patients
at diagnosis and during their front-line treatment.
15
Survival curves were constructed by using the Kaplan–
Meier method, and the generalized Wilcoxon log-rank
test (Peto) was used to compare the curves. A P-value
<0.05 was considered to be statistically signiﬁcant.
Statistical analyses were performed using the Stats-
direct software (Statsdirects Ltd, Sale, UK).
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One hundred and one small round cell tumours
were analysed by immunocytochemistry with 5B14
mAb (Table 1). All the lymphoblastic lymphomas
(seven cases) and blastemic components of Wilms’
tumours (eight cases) were negative. Two out of six
Ewing’s sarcoma (33%) and three out of 11 Burkitt’s
lymphoma (27%) specimens were slightly immuno-
reactive (Table 1). Conversely, 6 ⁄ 9 rhabdomyo-
sarcoma (67%), 39 ⁄ 53 NB (74%) and 7 ⁄ 7
medulloblastoma (100%) specimens were positive. By
Table 1. Immunocytochemical analysis of 101 small blue cell tumours with 5B14 mAb
Tumours n Neg. (%) Pos. n Score* n Grade†
Lymphoblastic lymphoma 7 7 100 0 –
Wilms’ tumours 8 8 100 0 –
PNET ⁄ Ewing’s 6 4 66 2
03 0+ + +
02 1+ +
21 1+
Burkitt’s lymphoma 11 8 73 3‡




Rhabdomyosarcoma 9 3 33 6
03 0+ + +
42 0+ +
21 6+
Neuroblastoma 53 14 26 39
13 3 14 +++
92 7+ +
17 1 6 +
12 ±
Medulloblastoma 7 0 7
53 5+ + +
22 1+ +
01 1±
*0, no staining; 1, weak and partial membranous immunoreactivity in >10% of cells; 2, moderate membranous reactivity in
>10% of cells; 3, intense membranous reactivity in >10% of cells.
†±, 10–25% positive tumour cells; +, 25–50% positive tumour cells; ++, 50–75% positive tumour cells; +++, 75–100% positive
tumour cells.
‡Focal positivity.
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scored 3; two medulloblastomas, nine NB and four
rhabdomyosarcomas scored 2; 17 NB and two rhab-
domyosarcomas scored 1 (Table 1).
When semiquantitative analysis was performed, six
positive rhabdomyosarcoma specimens, three positive
Burkitt’s lymphomas, one positive Ewing’s sarcoma
and one positive medulloblastoma were graded + or ±
(Table 1). Conversely, 6 ⁄ 7 medulloblastomas (86%),
21 ⁄ 39 NB (54%) and one Ewing’s tumour were graded
+++ or ++. One medulloblastoma and the remaining
18 NB tumours had a lower grading (six samples +,
and 12 samples ±) (Table 1).
As shown in Figure 1, where two representative
negative specimens of lymphoblastic lymphoma and
Wilms’ tumour are included (panels A and B, respec-
tively), the membranous pattern of immunoreactivity
of 5B14 antibody was focal in Burkitt’s lymphomas
(Figure 1C) and Ewing’s sarcomas (not shown).
Conversely, intense reactivity was observed in rhabdo-
myosarcomas (Figure 1D) and medulloblastomas (not
shown). In NB specimens, 5B14 immunoreactivity was
highly heterogeneous. In addition to 26% of negative
samples (Table 1), both the intensity (score) and the
percentages (grade) of positive cells varied greatly
among the different samples (Figure 2A, B, score 3 and
score 1, respectively; Figure 2C, D, grade +++ and
grade +, respectively). In NB specimens, however, the
5B14 antibody preferentially stained areas of rosette
formation or of ganglion differentiation (Figure 3A, B,
respectively).
B7-H3, the antigen recognized by the 5B14 mAb,
has been shown to downregulate NK- and ⁄ or
T-mediated antitumour activity by interacting with a
AB
CD
Figure 1. Reactivity of 5B14 mAb in small round blue cell tumours. Lymphoblastic lymphomas (A) and blastematous components of Wilms’
tumours (B) were always negative. Three out of 11 Burkitt’s lymphoma specimens showed focal positivity (C) Several rhabdomyosarcomas (D),
as well as medulloblastomas (not shown) and neuroblastomas (NB) (see Figure 2), were positive. *Area corresponding to the inset. Original
magniﬁcation ·100, insets ·400.
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Figure 2. Different score and grade of 5B14 staining in neuroblastoma (NB). Representative NB with score 3 (A), score 1 (B), grade +++ (C) and
grade + (D). Original magniﬁcation ·100 (A–B), ·40 (C–D).
A B
Figure 3. Rosettes of neuroblastoma (NB) cells (A) and differentiating NB cells (B) stained with 5B14 antibody. Original magniﬁcation ·100.
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9 Based on the great
heterogeneity of 5B14 reactivity in NB tumours, we
sought to perform NB patients’ survival analysis by
stratifying them according to the 5B14 positivity in
their tumours. Initially, patients were stratiﬁed based
on the presence or absence of reactivity, but no
difference in survival was observed (not shown).
However, when patients were stratiﬁed according to
the presence or absence of high expression of B7-H3
(score 3 or grade ++ ⁄ +++) in their tumours, a highly
signiﬁcant difference was observed. As shown in
Figure 4, patients who scored 3 (Figure 4A) or
+++ ⁄ ++ (Figure 4B) had a worse event-free survival
than patients that scored <3 or were graded less than
++ (P = 0.019 and P = 0.0017, respectively). Inter-
estingly, the difference in event-free survival was
observed also when high-risk patients (stage 4) were
excluded from the analysis (Figure 4C, P = 0.021) and
when only patients with localized disease (stage 1–3)
were considered for analysis (Figure 4D, P = 0.011).
Discussion
We have shown that 74% of NB, 67% of rhabdomyo-
sarcomas and 100% of medulloblastomas were stained
by the 5B14 mAb, which recognizes the B7-H3
molecule.
9 Conversely, 100% of lymphoblastic lym-
phomas and the blastemic component of Wilms’
tumours were completely negative. Thus, this mAb
has a clinical utility in the differential diagnosis of small
round blue cell tumours. In particular, it may be a
useful tool for tumours presenting in an unusual
clinical context, when undifferentiated small blue cells
without neural, rhabdoid or epithelial differentiation
are observed in light microscopy.
Whereas 100% of medulloblastomas were positive,
5B14 showed a variable and limited speciﬁcity and
sensitivity for NB, rhabdomyosarcoma and Ewing’s
tumour, similarly to other commercial mAbs.
6 For
example, the identiﬁcation of NB cells usually relies on
the combination of CD99
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Figure 4. Kaplan–Meyer plots of event-free survival of neuroblastoma (NB) patients stratiﬁed according to absence ⁄ presence in their tumours of
score 3 positivity (all patients, A); grade +++ ⁄ ++ (all patients, B); score 3 positivity (stage 4 patients excluded, C); score 3 positivity (only stage
1, 2 and 3 patients, D).
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7 with NB84 positivity,
6 although skeletal
and extraskeletal Ewing’s tumours and PNETs may also
be NB84+.
6 Indeed, the anti-GD2 mAbs (GD2 is a NB-
associated marker) cannot be used on parafﬁn-embed-






21are also not NB-speciﬁc.
Thus, differential diagnosis of NB tumours may take
advantage of the combined use of NB84 and 5B14
mAbs. In this context, it is of note that the expression of
the (still unknown) NB84-reactive molecule
2 is limited
to the cytoplasm, whereas B7-H3, the antigen recog-
nized by 5B14 mAb, is a transmembrane glycoprotein
expressed on the cell surface. In addition, unlike
the antigen recognized by the NB84 mAb,
6 the
B7-H3 molecule seems to be expressed by both neural
crest- and tube-derived precursors, as demonstrated
by the absolute 5B14 positivity observed in medullo-
blastomas.
The fact that some NB tumours are 5B14) or faintly
5B14+ conﬁrms the great heterogeneity of this malig-
nancy
22 and suggests that in some NB neuronal
markers could be down-regulated. The ﬁnding that
high expression of B7-H3 in NB is associated with a
worse event-free survival merits further investigation.
This correlation, in fact, was also observed in patients
with localized disease (stage 1–3) and in those with
metastatic disease <1 year old (stage 4s). It is of note
that these patients generally have a good survival,
23
and few of them relapse and eventually die of the
disease. For these patients, Myc-N ampliﬁcation is the
only independent factor of bad prognosis.
24,25 In our
study, only four out of 53 NB tumours were Myc-N
ampliﬁed. Thus, the fact that high reactivity of the 5B14
mAb was associated with a worse prognosis supports
the tenet that high expression of B7-H3 surface mole-
cule, together with other factors such as age and MKI,
may help to identify patients at risk of relapse who may
take advantage of more careful follow-up.
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